Ofev

Active substance

nintedanib

Holder

Boehringer Ingelheim International GmbH

Status

Running

Indication

adult patients with non-IPF (idiopathic pulmonary fibrosis) chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype (PF-ILD's)

Public documents 

Approbation

Information for the patient

Informed consent

Last update

19/01/2021